Literature DB >> 26581612

Introducing Cytology-Based Theranostics in Oral Squamous Cell Carcinoma: A Pilot Program.

Anna Patrikidou1, Rosalia Maria Valeri2, Kyriaki Kitikidou3, Charikleia Destouni2, Konstantinos Vahtsevanos4.   

Abstract

We aimed to evaluate the feasibility and reliability of brush cytology in the biomarker expression profiling of oral squamous cell carcinomas within the concept of theranostics, and to correlate this biomarker profile with patient measurable outcomes. Markers representative of prognostic gene expression changes in oral squamous cell carcinoma was selected. These markers were also selected to involve pathways for which commercially available or investigational agents exist for clinical application. A set of 7 markers were analysed by immunocytochemistry on the archival primary tumour material of 99 oral squamous cell carcinoma patients. We confirmed the feasibility of the technique for the expression profiling of oral squamous cell carcinomas. Furthermore, our results affirm the prognostic significance of the epidermal growth factor receptor (EGFR) family and the angiogenic pathway in oral squamous cell carcinoma, confirming their interest for targeted therapy. Brush cytology appears feasible and applicable for the expression profiling of oral squamous cell carcinoma within the concept of theranostics, according to sample availability.

Entities:  

Keywords:  Angiogenesis; Biomarker; Cytology; Oral squamous cell carcinoma; Theranostics

Mesh:

Substances:

Year:  2015        PMID: 26581612     DOI: 10.1007/s12253-015-0017-6

Source DB:  PubMed          Journal:  Pathol Oncol Res        ISSN: 1219-4956            Impact factor:   3.201


  50 in total

1.  The utility of CD44, CD117 and CD133 in identification of cancer stem cells (CSC) in oral squamous cell carcinomas (OSCC).

Authors:  Cl Mărgăritescu; D Pirici; Cristiana Simionescu; A Stepan
Journal:  Rom J Morphol Embryol       Date:  2011       Impact factor: 1.033

2.  Angiogenesis and expression of platelet-derived endothelial cell growth factor in oral squamous cell carcinoma.

Authors:  R E Alcalde; N Terakado; K Otsuki; T Matsumura
Journal:  Oncology       Date:  1997 Jul-Aug       Impact factor: 2.935

3.  Expression of EGFR, HER2, HER3, and HER4 in metastatic squamous cell carcinomas of the oral cavity and base of tongue.

Authors:  T Ekberg; M Nestor; M Engström; H Nordgren; K Wester; J Carlsson; M Anniko
Journal:  Int J Oncol       Date:  2005-05       Impact factor: 5.650

Review 4.  Molecular markers of head and neck squamous cell carcinoma: promising signs in need of prospective evaluation.

Authors:  Phillipe Lothaire; Evandro de Azambuja; Didier Dequanter; Yassine Lalami; Christos Sotiriou; Guy Andry; Gilberto Castro; Ahmad Awada
Journal:  Head Neck       Date:  2006-03       Impact factor: 3.147

5.  Cetuximab and bevacizumab: preclinical data and phase II trial in recurrent or metastatic squamous cell carcinoma of the head and neck.

Authors:  A Argiris; A P Kotsakis; T Hoang; F P Worden; P Savvides; M K Gibson; R Gyanchandani; G R Blumenschein; H X Chen; J R Grandis; P M Harari; M S Kies; S Kim
Journal:  Ann Oncol       Date:  2012-08-16       Impact factor: 32.976

Review 6.  Liquid-based cytology in oral cavity squamous cell cancer.

Authors:  Roberto Navone; Monica Pentenero; Sergio Gandolfo
Journal:  Curr Opin Otolaryngol Head Neck Surg       Date:  2011-04       Impact factor: 2.064

7.  Prognostic significance of vascular endothelial growth factor protein levels in oral and oropharyngeal squamous cell carcinoma.

Authors:  B D Smith; G L Smith; D Carter; C T Sasaki; B G Haffty
Journal:  J Clin Oncol       Date:  2000-05       Impact factor: 44.544

8.  Cyclooxygenase-2 expression in squamous cell carcinoma of the oral cavity and pharynx: association to p53 and clinical outcome.

Authors:  Timo Atula; Johan Hedström; Ari Ristimäki; Patrik Finne; Ilmo Leivo; Mari Markkanen-Leppänen; Caj Haglund
Journal:  Oncol Rep       Date:  2006-09       Impact factor: 3.906

9.  RNA from brush oral cytology to measure squamous cell carcinoma gene expression.

Authors:  Joel L Schwartz; Suchismita Panda; Craig Beam; Laura E Bach; Guy R Adami
Journal:  J Oral Pathol Med       Date:  2008-02       Impact factor: 4.253

10.  Theranostic protein targeting ErbB2 for bioluminescence imaging and therapy for cancer.

Authors:  Xiao-Jian Han; Ling-Fei Sun; Yuki Nishiyama; Bin Feng; Hiroyuki Michiue; Masaharu Seno; Hideki Matsui; Kazuhito Tomizawa
Journal:  PLoS One       Date:  2013-09-17       Impact factor: 3.240

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.